Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients
Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 express...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Pathology and Oncology Research |
| Subjects: | |
| Online Access: | https://www.por-journal.com/articles/10.3389/pore.2023.1610951/full |
| _version_ | 1797218208816562176 |
|---|---|
| author | Adi Horesh Rena Pollack Rena Pollack Hovav Nechushtan Hovav Nechushtan Rivka Dresner-Pollak Rivka Dresner-Pollak Tzahi Neuman Tzahi Neuman |
| author_facet | Adi Horesh Rena Pollack Rena Pollack Hovav Nechushtan Hovav Nechushtan Rivka Dresner-Pollak Rivka Dresner-Pollak Tzahi Neuman Tzahi Neuman |
| author_sort | Adi Horesh |
| collection | DOAJ |
| description | Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 expression and molecular profile with the development of thyroid IRAEs in NSCLC patients.Methods: Single center, retrospective study including 107 NSCLC patients treated with PD-1/PD-L1 inhibitors from April 2016 to July 2020. All patients were euthyroid at baseline with at least two TSH measurements post-treatment initiation. The primary outcome was the difference in tumor PD-L1 expression in patients who developed any thyroid IRAEs versus those who remained euthyroid. Additional outcomes included development of overt thyroid dysfunction, the association of specific molecular alterations with thyroid IRAEs, and onset of thyroid IRAEs as a function of tumor PD-L1 expression.Results: Overall, 37 (34.6%) patients developed any thyroid dysfunction and 18 (16.8%) developed overt thyroid dysfunction. Tumor PD-L1 staining intensity was not associated with thyroid IRAEs. TP53 mutation was less likely to be associated with any thyroid dysfunction (p < 0.05) and no association was found between EGFR, ROS, ALK or KRAS mutations. There was no association between PD-L1 expression and time to develop thyroid IRAEs.Conclusion: PD-L1 expression is not associated with the development of thyroid dysfunction in advanced NSCLC patients treated with ICIs, suggesting that thyroid IRAEs are unrelated to tumor PD-L1 expression. |
| first_indexed | 2024-04-24T12:14:06Z |
| format | Article |
| id | doaj.art-e9177c5c795f417cb68feb1803ec7c2b |
| institution | Directory Open Access Journal |
| issn | 1532-2807 |
| language | English |
| last_indexed | 2024-04-24T12:14:06Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Pathology and Oncology Research |
| spelling | doaj.art-e9177c5c795f417cb68feb1803ec7c2b2024-04-08T09:40:38ZengFrontiers Media S.A.Pathology and Oncology Research1532-28072023-04-012910.3389/pore.2023.16109511610951Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patientsAdi Horesh0Rena Pollack1Rena Pollack2Hovav Nechushtan3Hovav Nechushtan4Rivka Dresner-Pollak5Rivka Dresner-Pollak6Tzahi Neuman7Tzahi Neuman8The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, IsraelThe Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, IsraelDepartment of Endocrinology and Metabolism, Hadassah-Hebrew University Medical Center, Jerusalem, IsraelThe Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, IsraelDepartment of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, IsraelThe Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, IsraelDepartment of Endocrinology and Metabolism, Hadassah-Hebrew University Medical Center, Jerusalem, IsraelThe Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, IsraelDepartment of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, IsraelBackground: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 expression and molecular profile with the development of thyroid IRAEs in NSCLC patients.Methods: Single center, retrospective study including 107 NSCLC patients treated with PD-1/PD-L1 inhibitors from April 2016 to July 2020. All patients were euthyroid at baseline with at least two TSH measurements post-treatment initiation. The primary outcome was the difference in tumor PD-L1 expression in patients who developed any thyroid IRAEs versus those who remained euthyroid. Additional outcomes included development of overt thyroid dysfunction, the association of specific molecular alterations with thyroid IRAEs, and onset of thyroid IRAEs as a function of tumor PD-L1 expression.Results: Overall, 37 (34.6%) patients developed any thyroid dysfunction and 18 (16.8%) developed overt thyroid dysfunction. Tumor PD-L1 staining intensity was not associated with thyroid IRAEs. TP53 mutation was less likely to be associated with any thyroid dysfunction (p < 0.05) and no association was found between EGFR, ROS, ALK or KRAS mutations. There was no association between PD-L1 expression and time to develop thyroid IRAEs.Conclusion: PD-L1 expression is not associated with the development of thyroid dysfunction in advanced NSCLC patients treated with ICIs, suggesting that thyroid IRAEs are unrelated to tumor PD-L1 expression.https://www.por-journal.com/articles/10.3389/pore.2023.1610951/fullPD-L1NSCLCimmune checkpoint inhibitorsimmune-related adverse eventsthyroid |
| spellingShingle | Adi Horesh Rena Pollack Rena Pollack Hovav Nechushtan Hovav Nechushtan Rivka Dresner-Pollak Rivka Dresner-Pollak Tzahi Neuman Tzahi Neuman Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients Pathology and Oncology Research PD-L1 NSCLC immune checkpoint inhibitors immune-related adverse events thyroid |
| title | Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients |
| title_full | Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients |
| title_fullStr | Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients |
| title_full_unstemmed | Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients |
| title_short | Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients |
| title_sort | tumor pd l1 expression and molecular profiling are not associated with immune checkpoint inhibitor induced thyroid dysfunction in advanced nsclc patients |
| topic | PD-L1 NSCLC immune checkpoint inhibitors immune-related adverse events thyroid |
| url | https://www.por-journal.com/articles/10.3389/pore.2023.1610951/full |
| work_keys_str_mv | AT adihoresh tumorpdl1expressionandmolecularprofilingarenotassociatedwithimmunecheckpointinhibitorinducedthyroiddysfunctioninadvancednsclcpatients AT renapollack tumorpdl1expressionandmolecularprofilingarenotassociatedwithimmunecheckpointinhibitorinducedthyroiddysfunctioninadvancednsclcpatients AT renapollack tumorpdl1expressionandmolecularprofilingarenotassociatedwithimmunecheckpointinhibitorinducedthyroiddysfunctioninadvancednsclcpatients AT hovavnechushtan tumorpdl1expressionandmolecularprofilingarenotassociatedwithimmunecheckpointinhibitorinducedthyroiddysfunctioninadvancednsclcpatients AT hovavnechushtan tumorpdl1expressionandmolecularprofilingarenotassociatedwithimmunecheckpointinhibitorinducedthyroiddysfunctioninadvancednsclcpatients AT rivkadresnerpollak tumorpdl1expressionandmolecularprofilingarenotassociatedwithimmunecheckpointinhibitorinducedthyroiddysfunctioninadvancednsclcpatients AT rivkadresnerpollak tumorpdl1expressionandmolecularprofilingarenotassociatedwithimmunecheckpointinhibitorinducedthyroiddysfunctioninadvancednsclcpatients AT tzahineuman tumorpdl1expressionandmolecularprofilingarenotassociatedwithimmunecheckpointinhibitorinducedthyroiddysfunctioninadvancednsclcpatients AT tzahineuman tumorpdl1expressionandmolecularprofilingarenotassociatedwithimmunecheckpointinhibitorinducedthyroiddysfunctioninadvancednsclcpatients |